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Four Months of Rifampin or Nine Months of Isoniazid 
for Latent Tuberculosis in Adults. 
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Tuberculosis constitutes a major health problem, with ap-
proximately 10.4 million new cases of tuberculosis worldwide 
reported in 2015. It has been estimated that one quarter of the 
global population has latent tuberculosis infection. Nowadays, 
given that enormous reservoir in mind, the treatment of la-
tent tuberculosis infection is a key part of the elimination of 
tuberculosis strategies, world widely. A 9-month regimen of 
isoniazid is usually used to prevent active tuberculosis in per-
sons with latent tuberculosis infection. However, this regimen 
has been associated with poor adherence rates and potentially 
severe adverse side effects, in terms of hepatotoxicity. In a trial 
conducted in nine countries, researchers randomly assigned 
adults with latent tuberculosis infection to receive treatment 
with a 4-month regimen of rifampin or a 9-month regimen of 
isoniazid for the prevention of confirmed active tuberculosis. 
The 4-month regimen of rifampin was not inferior to the 
9-month regimen of isoniazid for the prevention of active 
tuberculosis and was related to a higher rate of completion 
of treatment and better safety outcomes.
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Klebsiella pneumoniae carbapenemase (KPC)-producing K. 
pneumoniae (KPC-KP), has become one of the most important 
contemporary pathogens, especially in endemic areas, such 
as the Mediterranean. Several new diagnostic technologies 
have recently become available to allow increased rapidity of 
microbiologic diagnosis, including matrix-assisted desorption 
ionization-time of flight mass spectrometry (MALDI-TOF 
MS), rapid immunochromatography, rapid enzymatic assays 
(such as the Carba NP test), single cell automated time-lapse 
microscopy and molecular biology based assays. Because 
monotherapy appeared to be associated with higher mortality 
rates compared to combination therapy for the targeted treat-
ment of KPC-KP strains in observational studies, the use of 
combined regimens should be preferred in patients with severe 
KPC-KP infections. In combination treatment, meropenem 
may still be considered as an option for possibly enhancing 
bacterial killing, provided that the MIC of meropenem is 8 
mg/L and that a high-dose and prolonged infusion regimen is 
administered. Other plausible antibiotics, include polymyxins 
(colistin and polymyxin B), tigecycline, aminoglycosides, 
fosfomycin and ceftazidime-avibactam. Optimal treatment 
duration for KPC-KP infections is unclear. In retrospective 
studies, a mean duration of 2 weeks of treatment was reported 
to be efficacious.
Treatment of Infections by OXA‑48‑Producing 
Enterobacteriaceae.
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Carbapenemase-producing Enterobacteriaceae (CPE) 
poses global public health threat in terms of antimicrobial 
resistance. OXA-48 and its variants are unique carbapenemases 
with low-level hydrolytic activity toward carbapenems, but 
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no intrinsic activity against expanded-spectrum cephalospor-
ins. Despite the inability of OXA-48-like carbapenemases 
to hydrolyze expanded-spectrum cephalosporins, pooled 
isolates demonstrate high variable resistance to ceftazidime 
and cefepime, likely representing high rates of extended-
spectrum beta-lactamase (ESBL) co-production. In vitro data 
from pooled studies, suggest that avibactam is the most potent 
beta-lactamase inhibitor when combined with ceftazidime, 
cefepime, aztreonam, meropenem, or imipenem. Avibactam 
is a diazabicyclooctane, a non-beta-lactam beta-lactamase 
inhibitor, which may have the ability to inhibit OXA-48 
beta-lactamase by forming a stable covalent complex. Resist-
ance to novel avibactam combinations, such as imipenem-
avibactam or aztreonam-avibactam has not yet been reported 
in OXA-48 producers, although only a few clinical isolates 
have been tested. Although combination therapy is thought 
to improve the chances of clinical cure and survival in CPE 
infection, successful outcomes were seen in 70% of patients 
with infections caused by OXA-48-producing Enterobacte-
riaceae treated with ceftazidime-avibactam monotherapy. A 
carbapenem in combination with either amikacin or colistin 
has achieved treatment success in a few case reports, too. 
Uncertainty remains regarding the best treatment options 
and strategies for managing these infections. Newly available 
antibiotics such as ceftazidime-avibactam show promise; 
however, recent reports of resistance are really concerning. 
Newer choices of antimicrobial agents are truly required to 
combat this resistance problem.
